Sprouts CEO Jack Sinclair disposes of $1,390,572 in common shares

October 7 - ** Pharmaceutical company Lipocine (LPCN.O) saw its stock price rise 28% in pre-market trading to $2.7. ** Lipocine announced that (link) it has received approval from Health Canada for its oral testosterone replacement therapy drug, Tlando, for the treatment of male hypogonadism. ** In January 2024, Lipocine licensed the commercialization rights for Tlando in the US and Canada to the private company Verity Pharma. ** Lipocine is eligible to receive milestone payments of up to $259 million, as well as royalties ranging from 12% to 18% based on Tlando’s net sales. ** According to Lipocine, over 700,000 prescriptions for testosterone replacement therapy (TRT) are issued annually in Canada, with approximately 50% of patients reimbursed through private insurance. ** TRT is available in multiple formulations, including injections, oral medications, and topical gels. ** As of the previous trading session’s close, LPCN shares had declined by 73% year-to-date. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translations may be inaccurate or lack desired context, Reuters does not guarantee the accuracy of translated content and provides such translations for user convenience only. Reuters accepts no responsibility for any harm or loss resulting from the use of automated translation features.)

On October 7th, shares of the oilfield services company Helmerich & Payne (HP.N) rose 2% in pre-market trading to $40.4. H&P announced plans to deploy seven additional FlexRobotics systems for ExxonMobil (XOM.N) over the next 12 months. FlexRobotics is HP’s automated drilling platform technology. The company expects its operating margin to improve in fiscal year 2027 and reported strong performance in the fourth quarter. H&P remains committed to reducing its leverage ratio by the end of fiscal year 2027. As of the previous trading day’s close, the stock had risen 38.1% year-to-date. (For convenience, Reuters provides automated translations of its reports into several other languages. Automated translations may contain errors or not include the required context. Reuters does not guarantee the accuracy of automated translations and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)

On October 7 – After Google and Unity announced the launch of a new AI gaming platform (link), the share price of gaming platform Roblox (RBLX.N) dropped 4.8% in pre-market trading to $43.39. The platform jointly developed by Google (GOOGL.O) and Unity (U.N) allows users to generate and customize playable games using only text prompts, without programming. Roblox has been expanding its own AI creation suite (link), including the introduction of the "Build" text-to-game tool in July, as well as other generative AI features added for developers in September. As of the previous trading day's close, RBLX had fallen roughly 44% year-to-date. (For the convenience of non-English speakers, Reuters has automated translation of its reports into multiple languages. Since automated translation may contain errors or lack the required context, Reuters does not guarantee the accuracy of automated translations and provides them for the convenience of readers only. Reuters bears no liability for any damages or losses arising from the use of automated translation.)